Skip to main content

Australia and New Zealand Prothrombin Complex Concentrate Market Worth USD 40.4 Million at 10.9% CAGR by 2027 Owing to Rising Geriatric Population

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, India, Feb. 15, 2021 (GLOBE NEWSWIRE) — The Australia and New Zealand prothrombin complex concentrate market size is expected to experience considerable growth by reaching USD 40.4 million by 2027 while exhibiting a CAGR of 10.9% between 2020 and 2027. This growth is attributable to the increasing consumption of Vitamin K antagonists such as warfarin that is likely to surge the demand for advanced prothrombin complex concentrates in Australia and New Zealand. This information is published by Fortune Business Insights in its latest report, titled, “Australia and New Zealand Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Factor Deficiency and Congenital Coagulation Factor Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027.” The report further observes that the market stood at USD 17.8 million in 2019.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/australia-and-new-zealand-prothrombin-complex-concentrate-market-104761
The COVID-19 pandemic has affected several economies that are facing unprecedented loss. Owing to the lockdown announced by the government agencies and reduced labor force, several industries have been on a standstill with limited operational activities. However, a proactive combined effort from the government and other industries is anticipated to bring the economy back on track and aid in the industrial activities returning to pre-pandemic levels.Prothrombin complex concentrate (PCC) is manufactured after the removal of factor XI and antithrombin through a process of ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools. These concentrates are extensively used to treat and further prevent bleeding in the case of hemophilia B if a pure factor IX is not present.An Overview of the Impact of COVID-19 on this Market :The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.
Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/australia-and-new-zealand-prothrombin-complex-concentrate-market-104761
What does the Report Include?The market for Australia and New Zealand prothrombin complex concentrate report includes qualitative and quantitative analysis of several factors such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers different regions, contributing to the growth of the market. It includes the competitive landscape that involves the leading companies and the adoption of strategies to announce partnerships, introduce new products, and collaborate that will further contribute to the growth of the market between 2020 and 2027. Moreover, the research analyst has adopted several research methodologies such as SWOT and PESTEL analysis to extract information about the current trends and industry developments that will drive the market growth during the forecast period.Increasing Consumption of Vitamin K Antagonists to Surge DemandAs per an article published by The National Center for Biotechnology Information (NCBI), it is anticipated that at least 1%-2% of the total population takes warfarin therapy. Owing to its affordability, warfarin is widely consumed, however, this anticoagulation agent may lead to fatal bleeding disorders due to over-dependency. Therefore, this is expected to boost the demand for advanced prothrombin complex concentrates that aid in effective treatment and prevention of bleeding disorders. Moreover, supportive government initiatives to promote awareness regarding the adoption of PCC is expected to contribute to the Australia and New Zealand prothrombin complex concentrate market growth in the forthcoming years.
Quick Buy –  Australia and New Zealand Prothrombin Complex Concentrate Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104761
Hospitals and Ambulatory Surgical Centers to Hold Largest Market ShareBased on end-user, the hospitals and ambulatory surgical centers segment is expected to showcase considerable growth during the forecast period. This growth is ascribable to the factors such as the increasing number of invasive surgeries and the easy availability of prothrombin complex concentrates across several healthcare institutions in Australia and New Zealand.Australia and New Zealand Generated USD 17.8 Million in terms of Revenue in 2019The increasing number of specialty clinics and the growing number of geriatric population is expected to boost the Australia and New Zealand prothrombin complex concentrate market share in the forthcoming years.Contract Signing by Major Companies to Intensify Industry CompetitionThe market for Australia and New Zealand prothrombin complex concentrate is fragmented by the presence of prominent companies focusing on signing contracts with government agencies or other companies to expand their product portfolio. Additionally, other key players are striving to maintain their presence and gain a competitive edge over their rivals by adopting several organic and inorganic strategies that will favor the market growth.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/australia-and-new-zealand-prothrombin-complex-concentrate-market-104761
Industry Development:April 2018 –  Sanquin announced its multi-year agreement with Abbott, a leading company in transfusion medicine. Under the agreement, the company will supply primary serological equipment and consumables that further includes Abbott’s Alinity system for blood and plasma screening.
List of the Companies Operating in the Market for Australia and New Zealand Prothrombin Complex ConcentrateCSL Limited (Melbourne, Australia)Grifols, S.A. (Barcelona, Spain) Octapharma AG (Lachen, Switzerland)Kedrion S.p.A (Lucca, Italy)Sanquin (Amsterdam, The Netherlands)Takeda Pharmaceutical Company Limited (Mumbai, India)Other Prominent Players
Table of Contents:
IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsEpidemiology of Coagulation Factor Deficiency in Australia and New ZealandRecent Industry Developments – Partnerships, Mergers & AcquisitionsRegulatory Scenario – For Key CountriesAnalysis in Relation to Alternatives to PCCPCC Market: Reimbursement Scenario & Key Industry TrendsImpact of COVID-19 on PCC Market
Get your Customized Research Report:https://www.fortunebusinessinsights.com/enquiry/customization/australia-and-new-zealand-prothrombin-complex-concentrate-market-104761
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline.
Have a Look at Related Reports:
Immunomodulators Market worth USD 285.01 Billion at 6.3% CAGR; Enhancement of Supply Chain to Boost Growth amid COVID-19, reports Fortune Business Insights™Home Rehabilitation Products Market 2021, Size, Share, Growth, Trends, Opportunities, Revenue, Forecast Report 2021-2028Global Tendonitis Treatment Market 2021, Size, Share, Growth, Trends, Analysis, Revenue, Forecast ReportComputed Tomography (CT) Scanners Market to Exhibit a CAGR of 5.9% by 2027; FDA Approval for Hitachi’s Scenaria to Propel Growth, states Fortune Business Insights™Antibiotics Market to Exhibit a CAGR of 2.1% by 2027; Rising Incidence of Tuberculosis and Malaria to Spur Lucrative Opportunities, states Fortune Business Insights™
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/australia-and-new-zealand-prothrombin-complex-concentrate-market-10519

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.